17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens - PubMed (original) (raw)

17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens

G Girasole et al. J Clin Invest. 1992 Mar.

Abstract

The effect of 17 beta-estradiol on interleukin-6 (IL-6) synthesis was examined in murine bone marrow-derived stromal cell lines, normal human bone-derived cells, and nontransformed osteoblast cell lines from mice and rats. In all these cell types IL-6 production was stimulated as much as 10,000-fold in response to the combination of recombinant interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF alpha). Addition of 17 beta-estradiol in the cultures exerted a dose-dependent inhibition of IL-1-, TNF-, and IL-1 + TNF-induced production of bioassayable IL-6. Testosterone and progesterone (but not 17 alpha-estradiol) also inhibited IL-6, but their effective concentrations were two orders of magnitude higher than 17 beta-estradiol. 17 beta-estradiol also decreased the levels of the IL-6 mRNA. In addition, estradiol inhibited both TNF-induced IL-6 production and osteoclast development in primary bone cell cultures derived from neonatal murine calvaria. The TNF-stimulated osteoclast development was also suppressed by a neutralizing monoclonal anti-IL-6 antibody. This in vitro evidence suggests, for the first time, a mechanistic paradigm by which estrogens might exert at least part of their antiresorptive influence on the skeleton.

PubMed Disclaimer

Cited by

Sex-specific bi‑directional association between osteoporosis and depression from the national representative data of South Korea.
Shin MK, Kim H, Choi SH, Kim BJ, Kwon O. Shin MK, et al. Sci Rep. 2022 Jun 9;12(1):9500. doi: 10.1038/s41598-022-13401-z. Sci Rep. 2022. PMID: 35680922 Free PMC article.
COVID-19 and Endocrine System: A Cross-Sectional Study on 60 Patients with Endocrine Abnormality.
Hadisi N, Abedi H, Shokoohi M, Tasdemir S, Mamikhani SH, Meshgi SH, Zolfagharzadeh A, Roshangar L. Hadisi N, et al. Cell J. 2022 Apr;24(4):182-187. doi: 10.22074/cellj.2022.8079. Epub 2022 Apr 27. Cell J. 2022. PMID: 35674019 Free PMC article.
Osteoimmunology: interactions of the bone and immune system.
Lorenzo J, Horowitz M, Choi Y. Lorenzo J, et al. Endocr Rev. 2008 Jun;29(4):403-40. doi: 10.1210/er.2007-0038. Epub 2008 May 1. Endocr Rev. 2008. PMID: 18451259 Free PMC article. Review.
Tissue-engineered endometrial model for the study of cell-cell interactions.
Schutte SC, James CO, Sidell N, Taylor RN. Schutte SC, et al. Reprod Sci. 2015 Mar;22(3):308-15. doi: 10.1177/1933719114542008. Epub 2014 Jul 16. Reprod Sci. 2015. PMID: 25031317 Free PMC article.
The role of IL-6 and osteoprotegerin in bone metabolism in patients with Graves' disease.
Omma T, Yücel Ç, Sertoğlu E, Fırat SN, Çulha C, Özgürtaş T. Omma T, et al. Turk J Med Sci. 2022 Apr;52(2):338-345. doi: 10.55730/1300-0144.5320. Epub 2022 Apr 14. Turk J Med Sci. 2022. PMID: 36161625 Free PMC article.

References

1. Endocrinology. 1991 May;128(5):2657-9 - PubMed
1. J Cell Physiol. 1989 Sep;140(3):478-82 - PubMed
1. J Cell Physiol. 1990 Oct;145(1):102-9 - PubMed
1. Exp Hematol. 1990 Aug;18(7):794-800 - PubMed
1. Anal Biochem. 1987 Apr;162(1):156-9 - PubMed

17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens - PubMed (original) (raw)